



1646
AT

PTO/SB/17 (05-03)

Approved for use through 04/30/2003. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003, Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT **(\$)** **0.00**

Complete if Known

Application Number	09/895,298-Conf. #4425
Filing Date	July 2, 2001
First Named Inventor	Steven M. Ruben
Examiner Name	E. O'Hara
Art Unit	1646
Attorney Docket No.	PZ035P1C1

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Order Other None
 Deposit Account

Deposit Account Number **08-3425**

Deposit Account Name **Human Genome Sciences, Inc.**

The Director is hereby authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description		Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1051	130	2051	65	Surcharge - late filing fee or oath
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet
1053	130	1053	130	Non-English specification
1812	2,520	1812	2,520	For filing a request for ex parte reexamination
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action
1251	110	2251	55	Extension for reply within first month
1252	410	2252	205	Extension for reply within second month
1253	930	2253	465	Extension for reply within third month
1254	1,450	2254	725	Extension for reply within fourth month
1255	1,970	2255	985	Extension for reply within fifth month
1401	320	2401	160	Notice of Appeal
1402	320	2402	160	Filing a brief in support of an appeal
1403	280	2403	140	Request for oral hearing
1451	1,510	1451	1,510	Petition to institute a public use proceeding
1452	110	2452	55	Petition to revive - unavoidable
1453	1,300	2453	650	Petition to revive - unintentional
1501	1,300	2501	650	Utility issue fee (or reissue)
1502	470	2502	235	Design issue fee
1503	630	2503	315	Plant issue fee
1460	130	1460	130	Petitions to the Commissioner
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)
1806	180	1806	180	Submission of Information Disclosure Stmt
8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))
1801	750	2801	375	Request for Continued Examination (RCE)
1802	900	1802	900	Request for expedited examination of a design application
Other fee (specify)				

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) **0.00**

** or number previously paid, if greater; For Reissues, see above

Complete (if applicable)

SUBMITTED BY				
Name (Print/Type)	Mark J. Hyman	Registration No. (Attorney/Agent)	46,789	Telephone (240) 314-1224
Signature	<i>Mark J. Hyman</i>		Date	August 15, 2003



RESPONSE UNDER 37 C.F.R. §1.116 - EXPEDITED PROCEDURE
GROUP ART UNIT 1646

VIA HAND DELIVERY AUGUST 15, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ruben et al.

Attorney Docket: PZ035P1C1

Application No.: 09/895,298

Group Art Unit: 1646

Filed: July 2, 2001

Examiner: O'Hara, E.

For: Protein HPRBF19

RECEIVED

AUG 19 2003

TECH CENTER 1600/2900

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.116 TO PAPER NO. 9

Mail Stop AF

Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

In response to the Office Communication mailed June 18, 2003 (Paper No. 9), please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith a Fee Transmittal Sheet (in duplicate) with appropriate fee.

Amendment to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 8 of this paper.